

April 2022 PDL/DUR Board Meeting Minutes

Date: April 27, 2022

Members Present: King, Blake, Blank, Brown, Caldwell, Jost, Nauts

Members Absent: Anglim, Maxwell, McGrane, Putsch, Stone

Others Present: Shannon Sexauer, Dani Feist, Katie Hawkins (DPHHS); Kathy Novack (Magellan); Bahny, Barnhill, Erickson, Opitz, Woodmansey (MPQH); and representatives from the pharmaceutical industry.

Introductions: Tony King opened the meeting.

Meeting Minute Review: The meeting minutes from the March 23, 2022 PDL meeting were approved as written.

Public Comment: Speaker information is as follows:

- Mariola Vazquez, Atopic Dermatitis - Adbry®
- Chase Williams – Hepatitis C - Epclusa®
- Tia Nguyen – Immunomodulators, Atopic Dermatitis - Dupixent®

Department Update: No Department update.

PREFERRED DRUG LIST MEETING

Results of the Board review of Group 3 (Red category):

CLASS	DRUG NAME	2022 RECOMMENDATIONS	Grandfathered
ACNE AGENTS	Winlevi® - ND Twynéo® - ND	<u>BENZOYL PEROXIDE COMBOS</u> – Class effect. <u>BENZOYL PEROXIDE AGENTS</u> – Class effect. <u>CLINDAMYCIN AGENTS</u> – Class effect. <u>SODIUM SULFACETAMIDE AGENTS</u> – Class effect. <u>TOPICAL RETINOIDS & COMBOS</u> – Class effect. <u>ERYTHROMYCIN TOPICAL</u> – Class effect.	No
ANTI-ALLERGENS, ORAL	Ragwitek® - NI	Continue with PA criteria.	No
ANTIBIOTICS, GI	Solosec® - NI	Must have metronidazole and vancomycin.	No
ANTIFUNGALS, ORAL	Brexafemme® - ND Noxafil® - NI	Must have terbinafine and fluconazole. Must have 1 of clotrimazole or nystatin. Continue PA criteria on ketoconazole.	No

ANTIPARASITICS, TOPICAL	Natroba® - NI	Therapeutic alternatives. Continue PA criteria.	No
ANTIVIRALS, ORAL (HSV/INFLUENZA)	Xofluza® - NI	<u>HSV Antivirals</u> - Class effect. <u>INFLUENZA Antivirals</u> - Must have both oseltamivir and baloxavir marboxil.	No
BLADDER RELAXANTS	Gemtesa® – ND Myrbetriq®, Toviaz® – NI	Class effect. Must have 1 long-acting agent (either by half-life or dosage form).	No
CYTOKINES & CAM ANTAGONIST	Cibinqo® - ND Cosentyx®, Orencia®, Rinvoq®, Skyrizi®, Xeljanz/XR® - NI	Therapeutic alternatives. Do not add anakinra (Kineret®) due to inferior efficacy and increased toxicity. Grandfather.	Yes
GLUCOCORTICIDS, INHALED	ArmonAir® - NI	Class effect.	No
GLUCOCORTICIDS, ORAL	Tarpeyo® - ND	<u>SHORT ACTING</u> - cortisone, hydrocortisone - Therapeutic alternatives. <u>INTERMEDIATE ACTING</u> - methylprednisolone, prednisone, and prednisolone- Therapeutic alternatives, must include a dosepak. <u>LONG ACTING</u> - betamethasone, dexamethasone - Therapeutic alternatives. <u>BUDESONIDE</u> - Must have 1 budesonide. <u>DEFLAZACORT</u> - Continue PA criteria.	No
HEPATITIS C AGENTS	Eplusa®, Mavyret®, Zepatier® - NI	<u>RIBAVIRINS</u> - Class effect. <u>PEGYLATED INTERFERONS</u> - Do not add. <u>ALL OTHERS</u> - Therapeutic alternatives. Must have a pangenotypic agent. Continue with existing PA criteria. Grandfather.	Yes
IMMUNOMODULATORS, ATOPIC DERMATITIS	Opzelura®, Adbry® - ND Dupixent® - NI	Therapeutic alternatives. Continue PA criteria.	No
IMMUNOSUPPRESSANTS	Rezurock® - ND Prograf® - NI	Must have an entity of azathioprine, cyclosporine, mycophenolate, sirolimus, and tacrolimus. Grandfather.	Yes
TETRACYCLINES	Nuzyra® - NI	Must have doxycycline.	No

The Board reviewed the blue category in advance of the meeting. Kathy from Magellan reported on new generics in this category. This category of drugs has no new clinically significant information since last review. Board recommendations for Group 2 (Blue category) from 2021 were retained, with the exception of removing the “*May Add Others*” to classes where it was mentioned in past meetings, per the Board’s request. The recommendations are as follows:

CLASS	2022 RECOMMENDATIONS	Grandfathered
ANTIBIOTICS, INHALED	Therapeutic alternatives.	No
ANTIBIOTICS, TOPICAL	Must have a mupirocin product.	No
ANTIBIOTICS, VAGINAL	Therapeutic alternatives.	No
ANTIFUNGALS, TOPICAL	Therapeutic alternatives for approved indications.	No
ANTIHISTAMINES, MINIMALLY SEDATING	Class effect. Must have one single ingredient agent.	No
ANTINEOPLASTIC AGENTS, TOPICAL	Therapeutic alternatives.	No
ANTIPSORIATICS, TOPICAL	Class effect. Must have one topical formulation and a scalp formulation. Continue PA criteria.	No
ANTIVIRALS, TOPICAL	Class effect.	No
BPH AGENTS	<u>ALPHA BLOCKERS</u> - Class effect. <u>ANDROGEN HORMONE INHIBITORS/COMBOS</u> - Class effect. <u>PDE-5 for BPH</u> - tadalafil will be non-preferred. Continue with PA criteria.	No
BRONCHODILATORS, BETA AGONISTS	<u>BETA AGONIST, LONG-ACTING</u> - Class effect. <u>BETA AGONIST, SHORT-ACTING</u> - Class effect.	No
CEPHALOSPORINS & RELATED AGENTS	<u>2nd GENERATION</u> - Class effect. <u>3rd GENERATION</u> - Class effect.	No
COPD AGENTS	Class effect. Must have a nebulizer product and a long-acting combination product.	No
EPINEPHRINE, SELF- INJECTED	Class effect.	No
FLUOROQUINOLONES, ORAL	<u>2nd GENERATION</u> - Class effect. Must have ciprofloxacin. <u>3rd GENERATION</u> - Class effect.	No
IMMUNOMODULATORS, TOPICAL	Class effect.	No
INTRANASAL RHINITIS AGENTS	<u>NASAL STEROIDS</u> - Class effect. <u>NASAL ANTIHISTAMINES & OTHERS</u> - Class effect.	No
LEUKOTRIENE MODIFIERS	Must have montelukast.	No

MACROLIDES & KETOLIDES	Class effect. Must have azithromycin, clarithromycin, and erythromycin.	No
METHOTREXATE AGENTS	Must have one oral and one injectable agent.	No
ROSACEA AGENTS, TOPICAL	Must have one metronidazole product.	No
SMOKING CESSATION	Must have a nicotine patch and either nicotine gum or lozenge. Must have varenicline.	No
STEROIDS, TOPICAL	<u>LOW, MEDIUM, HIGH, and VERY HIGH POTENCY CLASSES</u> -Class effect for each class; must have 1 cream and 1 ointment from each category.	No

There were no Group 1 (green category) drugs to review.

Meeting adjourned at 2:48pm.

The final PDL meeting for 2022 will be held on May 25th at 1:00pm, in this same format.